A Study to Assess Safety and Tolerabiltiy Associated With a Switch From Oral Antipsychotic Medications to Long-acting Injectable Risperidone in Patients With Schizophrenia.

NCT00034775 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

141

Enrollment

INDUSTRY

Sponsor class

Conditions

Schizophrenia
Psychotic Disorders

Interventions

DRUG: risperidone

Sponsor

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.